Ziconotide intrathecal treatment, long-term experience  by Kleiber, J.-C. et al.
a Service de neurochirurgie, hôpital Maison-Blanche, CHU de Reims, 51092
Reims, France
bUnités de médecine physique et de réadaptation, hôpital Sébastopol, CHU de
Reims, Reims, France
c Unités de chirurgie traumatologique et orthopédique, France
d Centre de MPR, UGECAM, Charleville Mèzière, France
*Corresponding author.
E-mail address: pperuzzi@chu-reims.fr
Keywords: Chronic pain; Organization; Integration; Interdisciplinary; Com-
plex intervention
Introduction.– The treatment of complex neuro-orthopedic disorders involves
the integration of several medical specialty. The purpose of this work is to
quantify the medicochirurgical collaboration in handicap care, at the University
Hospital of Reims.
Method.– Retrospective descriptive study conducted at the University Hospital
of Reims between 1st January 2006 and 31 December 2012. Successive
inclusion of all adult patients who have surgery after multidisciplinary decision
MPR-neurosurgery–orthopedics. Results are classified by type of symptom.
Results.– Four hundred twenty-seven patients received at least one neurosurgery
over this period.
Treatment of muscle hypertonia and dystonia:
– selective neurotomy in lower limbs: 67 (16%), 51 (76%) with tenotomy, 14
(21%) with tendon transpositions and 12 (18%) with arthrodesis;
– selective neurotomy in upper limbs associated with tenotomy: 32 (7.5%), 7
(22%) with joint release;
– intrathecal baclofen pump: 64 (15%) with 5/64 (7.8%) associated with
morphine and/or ziconotide injection.
Pain:
– intrathecal morphine or ziconotide pump for non-cancer pain: 115 (27%);
– posterior cord stimulation: 112 (26%), with 37 (33%) multi-column electrodes
for chronic lumbosacral radicular pain;
– cortical stimulation for face and upper limb chronic pain: 34 (8%), and for
tinnitus: 12 (2.8%);
– percutaneous stimulation for low back pain: 4 (1%);
– percutaneous stimulation for greater occipital nerve neuralgia: 13 (3%).
Discussion/Conclusion.– The collaboration of neurosurgeon, orthopedics
surgeon and PMR doctor is a guarantee of quality, efficiency and access to
optimal care. The number of surgery for eachpatient is reduced as their length. This
working together should be generalized. If the number of anesthetics per patient is
reduced, number of acts increases (pump fills, neurostimulators and pump
adjustment). This integrate collaboration induces better management of patients.
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Introduction.– Consequence of nerve and central nervous system lesion,
treatment of neuropathic pain is difficult. Only a third of patients has a benefit of
medication (anti-epileptic or antidepressure treatment). Cortical stimulation
represents a major progress for chronics and rebels pain.
Initially for thalamic pain, cortical stimulation is developed in other indications
with specifics results.
Patients et methods.– Reviewing from neurosurgicals files of Reims center,
between 2004 to 2012: 27 files, 12 females and 15 males, between 31 to 60 years
old. Three kinds of neuropathic pain: from medullar lesion (trauma, post-
surgery, syringomyelia. . .), from cranial lesion (vascular, tumoral. . .), and from
nerve lesion (facial nevralgia, phantom limb, algodystrophia. . .).
All patients were treated with an effective transcranial stimulation (rTMS)
before surgery.
Assessment of patient pain (EVA) and quality of life according to etiology and
length of time. Study of evolution of symptoms in time.
Results.– Improvement of pain changes between 50% to 100%. No difference
between male and female. Peripheral pain is quickly stabilised (6 months), with
a better improvement (70%) and a great stability in time.
In regard of brain etiology, stroke are still the best indication, but tumoral lesion
are less adequate (50%), nevertheless the low population (n = 2). Stimulation
intensity is lower (2.0 V).
Regarding medullar lesions, results are disappointing (55%). The stabilisation
takes time (2 years) and the pain changes with atmospheric conditions.
Stimulation intensity is stronger (3.5 V) and is disappointed. The drugs are equal.
Conclusion.– In theory, cortex stimulation is a treatment of a symptom no
matter of the etiology.
Phantoms limbs and algodystrophia had a bad reputation. In this study, the
results are satisfactory, specially in long term.
But medullar lesions are more disappointing, but cortex stimulation is still the
last possibility of treatment.
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Introduction.– Intrathecal ziconotide has shown effectiveness in chronic pain
treatment. We studied its long-term tolerance and efficiency.
Patient.– Thirty-nine patients have been treated with a continuous intrathecal
infusion of ziconotide, 16 female and 23 male, average age 58 years old [36;
79]. Twenty-four had chronic lomboradicular pains, 9 had cancer related pain
(among them 4 were at a palliative stage), 4 spine injuries, 1 cerebral palsy et 1
peripherical nerve lesion. Eleven received ziconotide only, 15 an association of
ziconotide and morphine, 6 a tritherapy associating ziconotide, morphine and
ropivacain and 7 had ziconotide, morphine and baclofene.
Results.– The average follow-up was 18.5 months [5; 48], 14/39 (36%) were
treated for more than 24 months. The average decrease of pain intensity was
equal to 31 mm on visual analog pain scale, from 68 to 37 after ziconotide
introduction. Average ziconotide posologies were 3.1 mg per day [0.5; 6.5].
Seventeen (44%) out of 39 patients suffered from side effects, treatment had to
be stopped for 13/39 (33%) with a full recovery after treatment interruption.
Most of the side effects occurred during the first semester of our experience of
ziconotide use due to a quick posology increase. The commonest side effects
were: nausea, dizziness, ataxia, visual and/or auditry hallucination. No
treatment failure has been notice for our 4 years of practice.
Conclusion.– Intrathecal ziconotide is still quite efficient and well tolerated
even after 4 years of continuous administration. There is no complication if the
posology is inferior to 4 mg per day. For cancer related pains, ziconotide has to
be introduced as early as possible, for long survivors it remains efficient (more
than 40 months in our population). Multiple associations are possible and
efficient even if ziconotide stability has to be studied in these conditions.
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